Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism
Bibliographic record
Abstract
Abstract Background Venous thrombo-embolism (VTE) occurs in up to 10% of pediatric patients with acute lymphoblastic leukemia (ALL). While anticoagulation is the mainstay of treatment, the optimal duration of therapeutic and/or prophylactic anticoagulation remains unclear. Aims To compare VTE progression/recurrence and bleeding rates based on duration of anticoagulation among pediatric patients treated for ALL with a history of central venous catheter (CVC)-related VTE, with duration of anticoagulation categorized as standard (i.e. until the end of asparaginase's expected effect or earlier) or extended (later than asparaginase's expected effect). Methods We performed a retrospective cohort study from three hospitals. Permission from the research ethics board was obtained at each institution. The cohort consisted of pediatric patients aged 1-21 years old with newly diagnosed ALL (2010-2023) receiving asparaginase-containing chemotherapy regimen who experienced a radiologically proven catheter-related VTE requiring medical intervention. Both symptomatic and clinically unsuspected VTEs were considered. The primary effectiveness outcome was time to VTE progression/recurrence. Safety outcomes were time to major bleeding and to clinically relevant non-major (CRNM) bleeding. All outcomes were defined using ISTH criteria (Mitchell, J Thromb Haemost, 2023). Asparaginase's expected effect was based on asparaginase formulation. Patients' characteristics are presented descriptively. We performed Cox proportional hazard models, with death considered a competing event, to compare rates of a) VTE progression/recurrence and b) CRNM bleeding, based on duration of anticoagulation. Results We included 109 patients (median age at ALL diagnosis: 9 years, interquartile range [IQR]: 4-13, 58% male) with ALL of B-cell (78%), T-cell (20%), or mixed/bilineage phenotype (2%). Most patients (104/109, 95%) received Dana-Farber Cancer Institute-based chemotherapy regimens. Patients had a median of 2 CVCs (IQR: 2-3); peripherally inserted central catheters were typically the first CVC (96/109, 88%) followed by totally implanted catheters as second CVC (57/88, 65%). Pegaspargase was the most common asparaginase used (91%). Index VTE occurred at a median of 75 days (IQR: 25-182) following ALL diagnosis. Anticoagulation was used in 106/109 (97%) of patients. The preferred initial agent was enoxaparin (101/106, 95%) and median duration of anticoagulation was 6.4 months (IQR: 3.2-9.5). Anticoagulation was stopped before and after the end of asparaginase's expected effect in 46 (43%) and 40 (38%) of patients, respectively, while 20 patients (19%) had extended anticoagulation, typically until CVC removal. Overall, 19 patients (17%) sustained a VTE recurrence/progression, at a median of 63 days (IQR: 32-280) following index VTE. Eight events were progression (5/8 symptomatic, all while on anticoagulation), and 11 were recurrences (7/11 symptomatic, 7/11 while on anticoagulation). Of 15 patients on anticoagulation at time of VTE recurrence/progression, 10 were receiving therapeutic doses and 5 were receiving prophylactic doses. Duration of anticoagulation did not predict VTE recurrence/progression (extended vs. standard: HR: 1.76, 95% CI: 0.57-5.39, p=0.323). Major bleed was rare, occurring in 3 (2.8%) patients. Two major bleeds were intracranial hemorrhage occurring within the first week of therapeutic anticoagulation in patients with systemic fungal infections; one was an intracranial bleeding following a stroke. CRNM bleed occurred in 2/20 patients on extended anticoagulation and 3/86 patients on standard anticoagulation (HR: 3.01, 95% CI: 0.55-16.60, p=0.205).Conclusions: VTE progression/recurrence following a first VTE occurred in 17% of children and adolescents with ALL. In this retrospective analysis, extended anticoagulation was not associated with a reduced risk of VTE progression/recurrence. This could suggest that an extended anticoagulation approach is not more effective or could reflect confounding by indication where patients considered at higher risk of progression/recurrence received longer antithrombotic treatment. Overall, in our cohort, the risk of VTE progression/recurrence appeared higher than the risk of major and/or CRNM bleeding. Further investigation into alternative approaches to reduce VTE progression/recurrence is warranted in children and adolescents with ALL receiving asparaginase-containing regimens.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.008 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".